ClinicalTrials.gg
RecruitingNCT04760522GE-MEDUpdated Nov 29, 2023

Genome-based Management of Patients in Precision Medicine (Ge-Med) Towards a Genomic Health Program

An interventional study of WGS Diagnostic: Blood take for genetic diagnostic in Rare Diseases and Genetic Predisposition to Disease, sponsored by University Hospital Tuebingen. Recruiting at 1 site in Germany. Per ClinicalTrials.gov, last updated 2023-11-29.

Sponsored by University Hospital Tuebingen · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Jun 2021; still recruiting 5 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12,000
Allocation
Not applicable
Sex
All
01

Study summary

The GE-MED APPROACH project will enroll patients (n = appr. 12.000) with unclear molecular cause of the disease, suspected genetic cause of the disease without detailed molecular analysis like Whole Exome Sequencing (WES).

The novelty of this study is to integrate genomic health concepts into immediate clinical care. To achieve these goals, a novel structure for the Triple P (3P) concept of personalized medicine (Personalized, Predictive, Preventive) integrated into a well-established health care system and associated with novel decentralized Disease Analysing Task Forces (DATF) will be implemented.

The overall goal of this study is to implement, for the first time, Whole Genome Sequencing (WGS) analysis as a first line diagnostic test for all clinical indications such as Rare Disease (RD )and familial cancer syndromes.

02

Conditions studied

  • Rare Diseases
  • Genetic Predisposition to Disease

Keywords

  • Rare Diseases
  • Genetic Predisposition
  • Whole Exome Sequencing (WES)
  • Whole Genome Sequencing (WGS)
  • Familial cancer syndromes
  • Polygenic Risk Scores (PRS)
03

In context

Rare Diseases

592 studies on the registry are indexed under Rare Diseases; 125 are open to participants now.

This study's planned enrollment of 12,000 is above the median of 45 across 339 interventional studies indexed under Rare Diseases.

Browse Rare Diseases studies →

Lead sponsor

University Hospital Tuebingen is the lead sponsor of 492 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unclear molecular cause of the disease
  • Suspected genetic cause of the disease

Exclusion criteria

Exclusion Criteria:

  • Missing of the patient and if applicable the legal representative
  • Previously performed WES or panel analysis
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
12,000 participants (estimated)

Study arms

  • Experimental
    WGS Diagnostic

    Both underage and adult persons (male and female) with diagnostically unsolved rare diseases who have been or are included into diagnostic care at the University Hospital Tübingen, Germany (UKT) and who are suspected of having a genetic cause of the disease. Study related procedures: Blood sampling, anamnesis including pedigree, Next Generation Sequencing (NGS) analysis and other omics analysis (transcriptomics, proteomics, metabolomics).

    Genetic: WGS Diagnostic: Blood take for genetic diagnostic

Interventions

  • GeneticWGS Diagnostic: Blood take for genetic diagnostic

    Blood sampling, short clinical characterization, WGS based sequencing, NGS analysis and other omics analysis (transcriptomics, proteomics, metabolomics).

06

What researchers measure

Primary outcomes

  1. Number of WGS analysis

    WGS analysis as a first line diagnostic test for all clinical indications

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The GE-MED APPROACH study will provide data in a pseudonymized manner to national and international databases set up to increase the diagnostic yield through advanced analysis tools and matchmaking against other cohorts

Supporting information: Analytic code

Time frame: Data will become available after analysis and unlimited.

Access criteria: Authorized users within the participating organizations.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jul 2026, 61 months after the start.

Of 36 interventional studies with no phase under Rare Diseases, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 60. This study's planned 61 months is above that.

Rare Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2021
First posted
Feb 18, 2021
StartActual
Jun 1, 2021
Primary completionEst.
Jul 2026
CompletionEst.
Jul 2027
Last update
Nov 29, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 29, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04760522
Responsible party
Sponsor
First posted
Feb 18, 2021
Start date
Jun 1, 2021
Primary completion
Jul 2026 (estimated)
Completion
Jul 2027 (estimated)
Last update
Nov 29, 2023

Study contacts

Olaf Rieß, Prof. Dr.
Contact
olaf.riess@med.uni-tuebingen.de
+49 7071 29 ext. 72323
Andreas Dufke, PD Dr.
Contact
andreas.dufke@med.uni-tuebingen.de
+49 7071 29 ext. 72190
Olaf Rieß, Prof. Dr.
study director · University Hospital Tübingen

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion